<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21693" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fenoldopam</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Szymanski</surname>
            <given-names>Michael W.</given-names>
          </name>
          <aff>Stony Brook University-Southampton Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Richards</surname>
            <given-names>John R.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Szymanski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Richards declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21693.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fenoldopam is used primarily for the lowering of blood pressure during episodes of severe hypertension. Fenoldopam has a unique mechanism of action compared to other antihypertensive medications: it is a dopamine (D1) receptor agonist that results in decreased peripheral vascular resistance primarily in renal capillary beds, thus promoting increased renal blood flow, natriuresis, and diuresis. Fenoldopam has minimal adrenergic effects. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of fenoldopam so that providers can direct patient therapy to optimal outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of fenoldopam.</p></list-item><list-item><p>Summarize the potential adverse events of fenoldopam.</p></list-item><list-item><p>Review the monitoring parameters for fenoldopam.</p></list-item><list-item><p>Summarize the importance of interprofessional communication, improving care coordination among the interprofessional team when initiating therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21693&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21693">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21693.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fenoldopam is used primarily for the lowering of blood pressure during episodes of severe hypertension.&#x000a0;Fenoldopam is used as an antihypertensive agent postoperatively and also intravenously to treat hypertensive crises. Since fenoldopam is the only intravenous agent that improves renal perfusion, it may be beneficial in hypertensive patients with chronic kidney disease.<xref ref-type="bibr" rid="article-21693.r1">[1]</xref></p>
      </sec>
      <sec id="article-21693.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fenoldopam has a unique mechanism of action compared to other antihypertensive medications: it is a dopamine (D1) receptor agonist that results in decreased peripheral vascular resistance primarily in renal capillary beds, thus promoting increased renal blood flow, natriuresis, and diuresis. Fenoldopam has minimal adrenergic effects.<xref ref-type="bibr" rid="article-21693.r2">[2]</xref></p>
        <p>It is important to understand the basics of vascular smooth muscle cell physiology and the role of D1 receptor agonism in severe hypertension. In arteries, the tunica media is composed of smooth muscle cells activated by various neurotransmitters, hormones, and mechanical perturbations. Examples of endogenous stimuli responsible for inducing arterial smooth muscle contraction include norepinephrine, angiotensin II, endothelin, and thromboxane-A2. Passive stretching also induces arterial smooth muscle contraction and can be of importance when describing the autoregulation of blood pressure. When an endogenous stimulus acts on a vascular smooth muscle cell, calcium (Ca++) is released either from the sarcoplasmic reticulum or from an influx across the cell membrane and binds to cytoplasmic calmodulin. The Ca++/calmodulin complex subsequently activates myosin light chain kinase (MLCK). MLCK phosphorylates myosin heads in the presence of adenosine triphosphate (ATP), thus enabling actin-myosin cross-bridge formation and smooth muscle contraction.<xref ref-type="bibr" rid="article-21693.r2">[2]</xref><xref ref-type="bibr" rid="article-21693.r3">[3]</xref></p>
        <p>Relaxation of smooth muscle occurs when there is decreased phosphorylation of myosin. There are documented mechanisms by which this can take place: reduced entry or decreased release of Ca++ from the sarcoplasmic reticulum and inhibition of MLCK by increased cyclic guanosine monophosphate (cGMP).<xref ref-type="bibr" rid="article-21693.r4">[4]</xref></p>
        <p>Two mechanisms achieve the removal of Ca++ ions from the cytoplasm. The primary mechanism is a plasma membrane-bound sodium (Na+)/Ca++ antiporter that effluxes one Ca++ ion and influxes three Na+ ions by utilizing the electrochemical gradient created by the Na+/potassium (K+) ATPase. The second mechanism by which Ca++ is removed from the cytoplasm is by a Ca++/ATPase located on the sarcoplasmic reticulum.</p>
        <p>The contraction and relaxation of vascular smooth muscle are the mechanisms by which changes in systemic vascular resistance (SVR) occur. Contraction of vascular smooth muscle causes a decrease in the cross-sectional area of the arterial lumen, thus increasing SVR and afterload on the heart. Interpreting how changes in SVR affect blood pressure involves understanding the physiologic relationship between mean arterial pressure (MAP), cardiac output (CO), and SVR. MAP is equivalent to CO multiplied by SVR. Simply stated, this means that CO and SVR directly correlate with MAP, such that increases in SVR cause a rise in MAP. This physiologic perturbation manifests clinically as high blood pressure. In contrast, by decreasing SVR, MAP decreases.</p>
        <p>Dopamine D1 receptors are located in the tunica media of arteries and exert their effects through a G-alpha stimulatory second messenger system. Upon ligand binding to D1-receptors, the alpha subunit dissociates from the intracellular domain of the transmembrane receptor and activates adenylate cyclase (AC). AC subsequently converts ATP to cyclic adenosine monophosphate (cAMP). All downstream effects get mediated by cAMP, the chief second messenger in this pathway.<xref ref-type="bibr" rid="article-21693.r5">[5]</xref></p>
        <p>Inside the cell, cAMP activates protein kinase A (PKA). PKA phosphorylates MLCK, thus causing its inactivation. Since myosin cannot undergo phosphorylated by MLCK, the cross-bridge formation between myosin and actin does not occur, rendering the arterial smooth muscle cell unable to contract. The result is the dilation of arteries producing decreased SVR, increased renal blood flow, natriuresis, and diuresis. These pharmacologic effects result in a decrease in blood pressure.<xref ref-type="bibr" rid="article-21693.r6">[6]</xref></p>
      </sec>
      <sec id="article-21693.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Fenoldopam administration is&#x000a0;via a continuous intravenous (IV) infusion&#x000a0;using an infusion pump.</p>
        <p>
<bold>Available Formulations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Generic: 10 mcg/mL (1 mL); 20 mg/2 mL (2 mL)</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>
<bold>Severe/Malignant Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initiate treatment at 0.01 to 0.3 mcg/kg/minute then increase by 0.05 to 0.1 mcg/kg/minute at 15 minute intervals until desired blood pressure is reached or a max of 1.6 mcg/kg/minute is reached.</p>
          </list-item>
          <list-item>
            <p>Renal impairment dosing: No adjustments</p>
          </list-item>
          <list-item>
            <p>Hepatic impairment dosing: No adjustments</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>
<bold>Severe Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initiate treatment at 0.2 mcg/kg/minute then increases by 0.3 to 0.5 mcg/kg/minute at 20 to 30 minute intervals until target blood pressure is reached or until a max of 0.8 mcg/kg/minute&#x000a0;is reached.<xref ref-type="bibr" rid="article-21693.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Pediatric renal impairment dosing: No adjustments</p>
          </list-item>
          <list-item>
            <p>Pediatric hepatic impairment dosing: No adjustments</p>
          </list-item>
        </list>
        <p><bold>Neonatal Dosing </bold>(Full-term or at least 2 kg)</p>
        <p>
<bold>Severe Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initiate treatment at 0.2 mcg/kg/minute then increases by 0.3 to 0.5 mcg/kg/minute at 20 to 30 minute intervals until target blood pressure is reached or until reaching a max of 0.8 mcg/kg/minute.</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The onset of action is 10 minutes in adults and 5 minutes in children. The half-life of fenoldopam is 5 minutes in adults and 3 to 5 minutes in children. Metabolization is by the liver, and excretion is primarily in the urine. The volume of distribution is 0.6 L/kg, and the duration is 1 hour.<xref ref-type="bibr" rid="article-21693.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21693.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common</bold>
</p>
        <p>Cardiovascular</p>
        <list list-type="bullet">
          <list-item>
            <p>Flushing</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
        </list>
        <p>&#x000a0;Central nervous system</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
        </list>
        <p>&#x000a0;Gastrointestinal</p>
        <list list-type="bullet">
          <list-item>
            <p>Nausea</p>
          </list-item>
        </list>
        <p>
<bold>Uncommon</bold>
</p>
        <p>Cardiovascular</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest pain</p>
          </list-item>
          <list-item>
            <p>Bradycardia</p>
          </list-item>
          <list-item>
            <p>ST-T abnormalities</p>
          </list-item>
          <list-item>
            <p>Ectopic beats</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
        </list>
        <p>Central Nervous System</p>
        <list list-type="bullet">
          <list-item>
            <p>Anxiety</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Insomnia</p>
          </list-item>
        </list>
        <p>Dermatologic</p>
        <list list-type="bullet">
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
        </list>
        <p>Endocrine and metabolic</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperglycemia</p>
          </list-item>
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Increased lactate dehydrogenase</p>
          </list-item>
        </list>
        <p>Gastrointestinal</p>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
        </list>
        <p>Genitourinary</p>
        <list list-type="bullet">
          <list-item>
            <p>Decreased urine output</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection</p>
          </list-item>
        </list>
        <p>Hematologic and oncologic</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemorrhage</p>
          </list-item>
          <list-item>
            <p>High white blood cell count</p>
          </list-item>
        </list>
        <p>Hepatic</p>
        <list list-type="bullet">
          <list-item>
            <p>increased serum transaminases</p>
          </list-item>
        </list>
        <p>Neuromuscular and skeletal</p>
        <list list-type="bullet">
          <list-item>
            <p>Myalgias&#x000a0;</p>
          </list-item>
        </list>
        <p>Ophthalmic</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased intraocular pressure</p>
          </list-item>
        </list>
        <p>&#x000a0;Renal</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased BUN</p>
          </list-item>
          <list-item>
            <p>Increased serum creatinine</p>
          </list-item>
        </list>
        <p>Respiratory</p>
        <list list-type="bullet">
          <list-item>
            <p>Difficulty breathing</p>
          </list-item>
          <list-item>
            <p>Nasal congestion</p>
          </list-item>
        </list>
        <p>&#x000a0;Constitutional</p>
        <list list-type="bullet">
          <list-item>
            <p>Fever</p>
          </list-item>
        </list>
        <p>
<bold>Risk C: Monitor</bold>
</p>
        <p>Increased hypotensive effects</p>
        <list list-type="bullet">
          <list-item>
            <p>Alfuzosin</p>
          </list-item>
          <list-item>
            <p>Second-generation antipsychotics (atypicals)</p>
          </list-item>
          <list-item>
            <p>Barbituates</p>
          </list-item>
          <list-item>
            <p>Benperidol</p>
          </list-item>
          <list-item>
            <p>Brimonidine</p>
          </list-item>
          <list-item>
            <p>Diazoxide</p>
          </list-item>
          <list-item>
            <p>Duloxetine</p>
          </list-item>
          <list-item>
            <p>Levodopa</p>
          </list-item>
          <list-item>
            <p>Molsidomine</p>
          </list-item>
          <list-item>
            <p>Naftopidil</p>
          </list-item>
          <list-item>
            <p>Nicergoline</p>
          </list-item>
          <list-item>
            <p>Nicorandil</p>
          </list-item>
          <list-item>
            <p>Nitroprusside</p>
          </list-item>
          <list-item>
            <p>Pentoxifylline</p>
          </list-item>
          <list-item>
            <p>Pholcodine</p>
          </list-item>
          <list-item>
            <p>Phosphodiesterase 5 inhibitors</p>
          </list-item>
          <list-item>
            <p>Prostacyclin analogs</p>
          </list-item>
          <list-item>
            <p>Quinagolide</p>
          </list-item>
          <list-item>
            <p>Yohimbe</p>
          </list-item>
        </list>
        <p>Decreased Antihypertensive Effects</p>
        <list list-type="bullet">
          <list-item>
            <p>Amphetamines</p>
          </list-item>
          <list-item>
            <p>Brigatinib</p>
          </list-item>
          <list-item>
            <p>Methylphenidate</p>
          </list-item>
        </list>
        <p>
<bold>Risk D: Consider an Alternate</bold>
</p>
        <p>Amifostine: Increased hypotensive effects; withhold antihypertensive therapy for 24 hours following infusion of amifostine if possible</p>
        <p>Obinutuzumab: Increased hypotensive effects; withhold antihypertensive for 12 hours before and 1 hour after infusion of obinutuzumab.</p>
        <p>
<bold>Risk X: Avoid</bold>
</p>
        <p>Bromperidol: Decreased effects of fenoldopam</p>
        <p>
<bold>Pregnancy: Risk Factor B</bold>
</p>
        <p>Safety and efficacy data for use in&#x000a0;pregnancy has not been established; however, no fetal harm was evident in animal studies.</p>
      </sec>
      <sec id="article-21693.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Allergy to propylene glycol and/or sulfites.<xref ref-type="bibr" rid="article-21693.r9">[9]</xref></p>
        <p>
<bold>Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia (within 6 hours of infusion)</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Angina (due to tachycardia)</p>
          </list-item>
          <list-item>
            <p>Glaucoma</p>
          </list-item>
        </list>
        <p>
<bold>Warnings</bold>
</p>
        <p>In pediatric patients, tachycardia may occur and may last up to 4 hours at doses greater than 0.8 mcg/kg/minute.</p>
      </sec>
      <sec id="article-21693.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Routine vitals such as blood pressure and heart rate in addition to serial electrocardiograms (ECGs), renal/hepatic function tests, and serum potassium require monitoring during fenoldopam infusion.</p>
      </sec>
      <sec id="article-21693.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A hypertensive crisis must be treated expeditiously and with the appropriate&#x000a0;medications. Managing&#x000a0;a hypertensive emergency requires an interprofessional team-based approach starting in the emergency department or the intensive care unit, which includes the active participation of nurses and physicians from many specialties. During a hypertensive crisis, the healthcare team must coordinate patient care, which includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serial blood pressure measurements</p>
          </list-item>
          <list-item>
            <p>Monitoring the patient for end-organ damage (cerebrovascular accident, myocardial infarction, among others)</p>
          </list-item>
          <list-item>
            <p>Vital signs&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ensure intravenous access</p>
          </list-item>
          <list-item>
            <p>Appropriate labs (renal function tests, liver function tests, serum potassium)</p>
          </list-item>
          <list-item>
            <p>Necessary tests (serial ECGs)</p>
          </list-item>
          <list-item>
            <p>Administration of appropriate&#x000a0;medication</p>
          </list-item>
          <list-item>
            <p>Possible consultation with a cardiologist&#x000a0;</p>
          </list-item>
        </list>
        <p>Besides the physicians, the nurse and pharmacist must be fully aware of the drug's adverse reactions and monitor the patient. The pharmacist should be fully aware that the drug is not administered to patients with glaucoma and asthma or used in combination with a beta-blocker for fear of inducing severe hypotension. Nurses must administer the drug according to appropriate dosing and protocol and report any adverse reactions to the healthcare team. All of the above represent examples of collaborative interprofessional communication necessary for successful fenoldopam therapy to optimize patient outcomes. [Level 5]</p>
        <p>Following the stabilization of the patient, other healthcare personnel outside the emergency department will have involvement in the patient's care. The type of&#x000a0;providers involved in outpatient care differs based on etiology. However, a family practitioner or internist will always be responsible for initiating the continuation of the patient's care.<xref ref-type="bibr" rid="article-21693.r10">[10]</xref></p>
        <p>
<bold>Evidence-Based&#x000a0;Outcomes</bold>
</p>
        <p>Fenoldopam has been demonstrated to have a renal protective effect in hypertensive patients with chronic kidney disease. However, a meta-analysis of many studies reveals that the drug can lower blood pressure effectively and decrease acute kidney injury, but in the long run, fenoldopam has no impact on renal replacement or the 30-day, in-patient mortality.<xref ref-type="bibr" rid="article-21693.r11">[11]</xref><xref ref-type="bibr" rid="article-21693.r12">[12]</xref>&#x000a0;[Level 2]</p>
      </sec>
      <sec id="article-21693.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21693&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21693">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21693/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21693">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21693.s10">
        <title>References</title>
        <ref id="article-21693.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yip</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Balasubramanian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ribeiro-Silva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sham</surname>
                <given-names>JSK</given-names>
              </name>
            </person-group>
            <article-title>Intraluminal pressure triggers myogenic response via activation of calcium spark and calcium-activated chloride channel in rat renal afferent arteriole.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>315</volume>
            <issue>6</issue>
            <fpage>F1592</fpage>
            <page-range>F1592-F1600</page-range>
            <pub-id pub-id-type="pmid">30089032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissell</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Browder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Flannery</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock.</article-title>
            <source>Ann Pharmacother</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>920</fpage>
            <page-range>920-927</page-range>
            <pub-id pub-id-type="pmid">29582666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanhoutte</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Shimokawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feletou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Endothelial dysfunction and vascular disease - a 30th anniversary update.</article-title>
            <source>Acta Physiol (Oxf)</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>219</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-96</page-range>
            <pub-id pub-id-type="pmid">26706498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Natarajan</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Eisner</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Armando</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pezzullo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dajani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The Renin-Angiotensin and Renal Dopaminergic Systems Interact in Normotensive Humans.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>265</fpage>
            <page-range>265-79</page-range>
            <pub-id pub-id-type="pmid">25977313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Drobatz</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Effect of Fenoldopam Continuous Infusion on Glomerular Filtration Rate and Fractional Excretion of Sodium in Healthy Dogs.</article-title>
            <source>J Vet Intern Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>1655</fpage>
            <page-range>1655-1660</page-range>
            <pub-id pub-id-type="pmid">27452198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <collab>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents</collab>
            <article-title>The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.</article-title>
            <source>Pediatrics</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>114</volume>
            <issue>2 Suppl 4th Report</issue>
            <fpage>555</fpage>
            <page-range>555-76</page-range>
            <pub-id pub-id-type="pmid">15286277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neill</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Labato</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Court</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics of intravenous fenoldopam in healthy, awake cats.</article-title>
            <source>J Vet Pharmacol Ther</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>202</fpage>
            <page-range>202-4</page-range>
            <pub-id pub-id-type="pmid">26763106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.</article-title>
            <source>Pediatrics</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-78</page-range>
            <pub-id pub-id-type="pmid">9024461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000e5;rtensson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bellomo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevention of renal dysfunction in postoperative elderly patients.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>451</fpage>
            <page-range>451-9</page-range>
            <pub-id pub-id-type="pmid">24999794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparative Efficacy of Drugs for Preventing Acute Kidney Injury after Cardiac Surgery: A Network Meta-Analysis.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-58</page-range>
            <pub-id pub-id-type="pmid">28819767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21693.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mas-Font</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ros-Martinez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Calvo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Villa-D&#x000ed;az</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aldunate-Calvo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moreno-Clari</surname>
                <given-names>E</given-names>
              </name>
              <collab>on belhaf of the Workgroup on Nephrology Intensive Care of the SEMICYUC</collab>
            </person-group>
            <article-title>Prevention of acute kidney injury in Intensive Care Units.</article-title>
            <source>Med Intensiva</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-126</page-range>
            <pub-id pub-id-type="pmid">28190602</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
